26vzmnrw022 10.3205/26vzmnrw022 urn:nbn:de:0183-26vzmnrw0229 Meeting Abstract Weigel Weigel C. C

Universitätsklinikum Düsseldorf, Klinik für Gastroenterologie, Hepatologie und Infektiologie, Düsseldorf, Deutschland

author Jahr Jahr V. V

Universitätsklinikum Düsseldorf, Klinik für Gastroenterologie, Hepatologie und Infektiologie, Düsseldorf, Deutschland

author Angendohr Angendohr C. C

Universitätsklinikum Düsseldorf, Klinik für Gastroenterologie, Hepatologie und Infektiologie, Düsseldorf, Deutschland

author Luedde Luedde T. T

Universitätsklinikum Düsseldorf, Klinik für Gastroenterologie, Hepatologie und Infektiologie, Düsseldorf, Deutschland

author Bock Bock H. H

Universitätsklinikum Düsseldorf, Klinik für Gastroenterologie, Hepatologie und Infektiologie, Düsseldorf, Deutschland

author German Medical Science GMS Publishing House

Düsseldorf

610 20260618 engl This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 License. Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). M0644 022 Niederrheinisch-Westfälische Gesellschaft für Chirurgie Gesellschaft für Gastroenterologie in Nordrhein-Westfalen e.V. 192. Jahrestagung der Niederrheinisch-Westfälischen Gesellschaft für Chirurgie, 34. Jahrestagung der Gesellschaft für Gastroenterologie Viszeralmedizin NRW 2026 Interdisziplinär Dortmund 20260618 20260619 022 TextBackground and objective: Statins are increasingly recommended in patients with liver cirrhosis due to their cardiovascular benefits and potential positive effects on portal hypertension and overall survival. However, patients with advanced cirrhosis are at increased risk for statin-associated muscle toxicity, particularly in the presence of additional risk factors.Method: We report the case of a 61-year-old male patient with primary sclerosing cholangitis and decompensated liver cirrhosis (Child–Pugh B) listed for liver transplantation. The patient presented to the transplant outpatient clinic with a sudden and marked elevation of serum transaminases despite previously stable liver function. Clinically, he complained of myalgia and muscle weakness. Laboratory investigations revealed a massive increase in creatine kinase levels accompanied by early deterioration of renal function. Further diagnostic work-up confirmed the diagnosis of severe rhabdomyolysis. A medication error in the context of ongoing statin therapy with atorvastatin was identified as the most likely trigger, facilitated by underlying liver cirrhosis and comorbid conditions.Result: Statin therapy was discontinued immediately. The patient was treated with intensive intravenous fluid substitution, close monitoring of renal function, electrolytes, body weight, and urine output, while diuretic therapy was continued. Under these measures, laboratory parameters and clinical symptoms improved rapidly, and renal replacement therapy was not required.Summary: This case highlights the importance of careful patient selection, dose adjustment, and close monitoring when prescribing statins in patients with advanced liver cirrhosis. Early recognition of myopathy symptoms and prompt intervention are crucial to prevent severe complications such as rhabdomyolysis. 0 0 0 0